[CAS NO. 2097938-51-5] R-10015
PRODUCTS SPECIFICATIONS [2097938-51-5]
DESCRIPTION [2097938-51-5]
Overview
| MDL | MFCD32067935 |
|---|---|
| Molecular Weight | 410.86 |
| Molecular Formula | C20H19ClN6O2 |
| SMILES | O=C(C1=CC=C2NC(C3CCN(C4=C5C(NC=C5Cl)=NC=N4)CC3)=NC2=C1)OC |
Summary
IC50 & Target
|
human LIMK1 38 nM (IC 50 ) |
In Vitro
R-10015 (100 μM; 0-4 hours) inhibits cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells
[1]
.
R-10015 inhibits HIV-1 DNA synthesis, nuclear migration, and virion release
[1]
.
R-10015 inhibits multiple viruses, including Zaire ebolavirus (EBOV), Rift Valley fever virus (RVFV), Venezuelan equine encephalitis virus (VEEV), and herpes simplex virus 1 (HSV-1)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | CEM-SS T cells |
| Concentration: | 100 μM |
| Incubation Time: | 0 hour,0.5 hour,1 hour,2 hours,4 hours |
| Result: | Inhibited cofilin phosphorylation directly through blocking LIM kinase in CEM-SS T cells. |
In Vivo
R-10015 (10 mg/kg; i.p.) displays none indication of toxicity. The result suggests the possibility of short-term use of LIMK inhibitors to block viral infections
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 6-8 weeks female C3H/HeN mice [1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Displayed none indication of toxicity. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 62.5 mg/mL ( 152.12 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4339 mL | 12.1696 mL | 24.3392 mL |
| 5 mM | 0.4868 mL | 2.4339 mL | 4.8678 mL |
| 10 mM | 0.2434 mL | 1.2170 mL | 2.4339 mL |